



Florida Pharmacy Association
610 North Adams Street
Tallahassee, Florida 32301

PRST STD
U.S. POSTAGE
PAID
TALLAHASSEE, FL
PERMIT #236

Who Should Attend?

Consultant Pharmacists
Nuclear Pharmacists
Nuclear Medicine Techs
Hospital Pharmacists
Community Pharmacists
Pharmacy Technicians

Continuing Education Programming

12 Hrs of General/Consultant CE
12 Hrs of Nuclear Track NRC/ JX-CE NMT
3 Hrs Laboratory Certification
2 Hrs Medication Errors
1 Hr HIV/AIDS Update

**Dual Track for Consultant and Nuclear
Pharmacists/Nuclear MedTechs
and
Initial Lab Certification Program**

Mid-Year Clinical Conference

October 1-3, 2010

Renaissance Orlando Airport Hotel

FLORIDA PHARMACY ASSOCIATION
(CONTINUING EDUCATION OPTIONAL PROGRAMS)

Friday, October 1, 2010

6:00-9:00PM

3 hrs GCE or RC

“Initial Certification for Ordering and Evaluation Laboratory Studies”

5:00pm Registration Desk Opens

Ordering and Evaluating Laboratory Data to Improve Patient Outcomes

Michael Thompson, PharmD, BCNSP, Florida A&M University, Professor of Pharmacy

Upon completion of the program, participants will be able to: Select appropriate laboratory tests for patient care; Identify and avoid common problems associated with the use, ordering and interpretation of laboratory values; Interpret laboratory values to monitor and improve pharmacotherapy; Discuss the legal aspects, restrictions and requirements for ordering and evaluation of laboratory studies; Document pharmaceutical care interventions.

UAN: 0165-0000-10-013-L04-P

Saturday, October 2, 2010

1:30-3:30PM

2 hrs GCE/TECH

“Reducing Medication Errors through Implementing a Continuous Quality Improvement Program”

Michael Jackson, RPh, CPh, FPA Executive Vice President & CEO

Upon completion of this activity pharmacists will be able to: Define elements of a Continuous Quality Improvement Program; Restructure a pharmacy practice to address quality related events; Analyze some common causes of quality related events; Implement an action plan to address quality of care in pharmacies with a goal towards error reduction and prevention; Recite quality improvement regulations for Florida pharmacies. Upon completion technicians will be able to: Define CQI; List the most common medication errors; Employ techniques to reduce medication errors by using CQI.

UAN: 0165-0000-10-025-L05-P

UAN: 0165-0000-10-025-L05-T

Sunday, October 3, 2010

1:30-2:30PM

1 hr GCE/TECH

“HIV/AIDS Update”

Michael Thompson, PharmD, BCNSP, Florida A&M University, Professor of Pharmacy. Upon completion of this presentation pharmacists will be able to: Identify new medications recently introduced to the market in the United States; Discuss indications, known mechanism of actions, dosages, contraindications, and common adverse effects; Discuss patient counseling information and the potential drug interactions; List new agents seeking approval in the United States. Upon completion technicians will be able to: Recognize new medications introduced to the market; Identify the use of the new agents; Describe proper storage and handling techniques.

UAN: 0165-0000-10-012-L02-P

UAN: 0165-0000-10-012-L02-T

*****LAST CHANCE TO RECEIVE
CONSULTANT LIVE CE
BEFORE THE RENEWAL CYCLE ENDS*****

SEPTEMBER 11-12, 2010

THE PHARMACIST ROLE IN MANAGING INFECTIOUS DISEASES

PGA NATIONAL RESORT & SPA

ROOM RATE \$129.00 PLUS TAX ~ CALL (800) 863-2819

DECEMBER 4-5, 2010

REGULATORY AND LAW

HYATT REGENCY SARASOTA

ROOM RATE \$145 PLUS TAX ~ CALL (800) 233-1234



Visit our website for specially priced Disney Theme Park Tickets for FPA conference attendees. Ticket savings are unavailable at the front gate of WDW Theme Parks. The deadline for savings via this form and web link is September 30, 2010!

Conference Schedule For Nuclear Pharmacist & MedTechs Recertification Continuing Education

Saturday Schedule: 6hrs NRC/NMT or 8 hrs GCE

Sunday Schedule: 6hrs NRC/NMT or 7hrs GCE

6:30am **Registration Desk Open**

7:00am-9:00am **Education: 2 hrs GCE/NRC/NMT**
Clinical Applications of Radioguided Surgery
George H. Hinkle, Jr., MS, RPh, BCNP, FASHP, FAPhA, Professor of Pharmacy Practice The Ohio State University – College of Pharmacy. Upon completion of this activity participants will be able to: Describe radioguided surgery and its impact on surgical procedures; Give three examples of a clinical application of radioguided surgery including the radiopharmaceuticals used for intraoperative detection; Discuss a future application of radioguided surgery and how it impacts the surgical decision making process.
UAN: 0165-0000-10-072-L04-P

9:00am-10:00am **Education: 1 hr GCE/NRC/NMT**
Oncologic PET/CT
Sebastian Obrzut, MD, Assistant Professor of Radiology, University of California – San Diego Medical Center. Upon completion of this activity participants will be able to: Describe recent advances of PET/CT imaging and its oncologic applications; Evaluate a variety of oncologic processes and metastatic disease using state of the art imaging protocols; Evaluate current and anticipated changes in reimbursement and government policies and regulations concerning PET/CT imaging.
UAN: 0165-0000-10-073-L04-P

10:00am-10:20am **Break**

10:20am-11:20am **Education: 1 hr GCE/NRC/NMT**
Pediatric PET/CT – Challenges, Pitfalls, and Normal Variants
Ruth Lim, MD, Instructor of Radiology, Harvard Medical School, and Assistant Radiologist, Massachusetts General Hospital. Upon completion of this activity participants will be able to: Describe how pediatric PET/CT patient preparation and image acquisition can be performed to optimize image quality and minimize radiation dose; Describe examples of interpretation pitfalls in pediatric PET/CT imaging that can lead to incorrect diagnoses; Review sites of normal physiologic FDG uptake in children to reduce the incidence of mis-interpretation as pathologic disease.
UAN: 0165-0000-10-074-L04-P

11:20pm-12:20pm **Education: 1hr GCE/NRC/NMT**
Clinical Value of Fusion Imaging in General Nuclear Medicine
Donald R. Neumann, MD, PhD, Director, Nuclear Oncologic Imaging, Cleveland Clinic Imaging Institute. Upon completion of this activity participants will be able to: Describe how SPECT/CT is utilized today and how it will impact Nuclear Medicine imaging in the future; Explain how low count studies can be acquired with SPECT/CT, processed with iterative or other new processing protocols, and then fused with CT; Discuss the feasibility and clinical utility of routine co-registration/fusion of SPECT studies (not acquired on a dedicated SPECT/CT system) with previously acquired or future CT.
UAN: 0165-0000-10-075-L04-P

12:20pm-1:20pm **Education: 1hr GCE/NRC/NMT**
Appropriate Use of Interventional Agents in Nuclear Medicine
Vivian S. Loveless, PharmD, BCNP, FAPhA, Associate Professor University Of Tennessee Health Science Center, College of Pharmacy. Upon completion of this activity participants will be able to: Identify the indications for interventional agents in nuclear medicine studies; Discuss the precautions and contraindications associated with interventional agents; Explain the mechanism(s) of action for interventional pharmaceuticals.
UAN: 0165-0000-10-076-L04-P

1:30pm-3:30pm **Education: 2 hrs GCE/TECH**
Reducing Medication Errors presented by Michael Jackson, RPh, CPh
UAN: 0165-0000-10-025-L05-P **UAN: 0165-0000-10-025-L05-T**
(See page 2 for details)

6:30am **Registration Desk Open**

7:00am-8:00am **Education: 1 hr GCE/NRC/NMT**
Monitoring Cancer Treatment with PET/CT
Sebastian Obrzut, MD, Assistant Professor of Radiology, University of California – San Diego Medical Center. Upon completion of this activity participants will be able to: Discuss the RECIST 1.1 criteria for assessment of tumor response to therapy with CT; Describe the EORTC criteria for assessment of tumor response with PET; Discuss the International Harmonization Project in Lymphoma criteria for response assessment; Evaluate the future directions of PET/CT in assessment of tumor therapy response.
UAN: 0165-0000-10-077-L04-P

8:00am-9:00am **Education: 1 hr GCE/NRC/NMT**
PET Physics and Recent Developments in PET Instrumentation
George El Fakhri, PhD, DABR Associate Professor of Radiology Harvard Medical School, and Director, Molecular Imaging Physics and Instrumentation Associate Director, PET Core Massachusetts General Hospital. Upon completion of this activity participants will be able to: Review general physics and instrumentation topics related to Positron Emission Tomography (PET) such as coincidence detection, spatial resolution, sensitivity, attenuation compensation, etc; Discuss the physical characteristics of available PET detectors; Describe the recent trends in PET/CT (4D-PET, Time of Flight PET) and PET/MRI
UAN: 0165-0000-10-078-L04-P

9:00am-10:00am **Education: 1 hr GCE/NRC/NMT**
Quality Control Review
Pat Zanzonico, PhD, Memorial Sloan-Kettering Cancer Center, Zuckerman Research Center. Upon completion of this activity participants will be able to: Identify common artifacts and anatomical assessment pitfalls in PET and PET/CT; Discuss the diagnostic value of PET/CT in common disease; Consider the uses of both PET and CT modalities separately and together along with other diagnostic modalities.
UAN: 0165-0000-10-079-L04-P


10:00am-10:20am **Break**

10:20am-11:20am **Education: 1 hr GCE/NRC/NMT**
Technical Aspects & Quality Control of SPECT/CT Artifacts & Pitfalls
Patrick F. Wojtylak, (R)(N), CNMT PET, Supervisor, Nuclear Medicine PET/CT. Upon completion of this activity participants will be able to: Review the development and history of SPECT/CT; Discuss the technical and operational aspects of an integrated SPECT/CT unit; Describe artifacts and pitfalls typically demonstrated in integrated SPECT/CT fused imaging.
UAN: 0165-0000-10-080-L04-P

11:20am-12:20pm **Education: 1 hr GCE/NRC/NMT**
Quality Related Events in Nuclear Pharmacy
Brigitte R. Nelson, MS, PharmD, BCNP, Director, Quality & Safety Triad Isotopes. Upon completion of this activity participants will be able to: Adapt the Florida Board of Pharmacy Continuous Quality Improvement Program (including patient safety and risk management) to quality related events in nuclear pharmacy; Discuss incident investigation and root cause analysis; Describe quality related metrics applied to the nuclear pharmacy setting to drive process improvement.
UAN: 0165-0000-10-081-L04-P

12:20pm – 1:20pm **Education: 1 hr GCE/NRC/NMT**
2010 and Beyond: The New Frontiers in Molecular Imaging
Henry M. Chilton, PharmD, MBA, Vice-President, Business Development (PET), Cardinal Health Nuclear Pharmacy Services
 Upon completion of this activity participants will be able to: Discuss the latest developments in PET radiopharmaceuticals, including new biomarkers that extend the diagnostic usefulness of PET in oncology beyond PET-FDG metabolic imaging; Describe PET tracer developments in imaging neurodegenerative disease, including differentiation of Alzheimer's disease from other types of dementia; Discuss the Society of Nuclear Medicine (SNM) Clinical Trials Network and potential opportunities involving the use of PET biomarkers to aid in clinical investigational trials for the determination of efficacy of new and novel therapeutic pharmaceuticals.
UAN: 0165-0000-10-082-L04-P

1:30pm-2:30pm **Education: 1hr GCE/TECH**
HIV/AIDS presented by Michael Thompson, PharmD, BCNSP
UAN: 0165-0000-10-012-L02-P **UAN: 0165-0000-10-012-L02-T**
(See page 2 for details)



The Florida Pharmacy Association is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. Up to 18 contact hours are available upon successful completion of the program through attendance and submission of completed attendance and evaluation forms. Statements of continuing pharmacy education will be mailed four to six weeks after the program. Consultant recertification approval number applied for and pending. Initial laboratory certification approval number is 20-260344. number is . **This is an ACPE knowledge based activity.**

Conference Schedule for General or Consultant Recertification "The Pharmacist Role in Managing Cardiovascular Diseases"

Saturday Schedule: 6hrs RC or 8hrs GCE/TECH

Sunday Schedule: 6hrs RC or 7hrs GCE/TECH

6:30am **Registration Desk Open**

7:00am-8:30am **Education: 1.5 hrs GCE/RC/TECH**
Cholesterol Management in Patients with Diabetes
Dana Brown, PharmD, Palm Beach Atlantic University, Pharmacy Professor. Upon completion of this activity pharmacists will be able to: Explain the association between diabetes and dyslipidemia; Identify risk factors for cardiovascular disease specific to patients with diabetes and dyslipidemia; Discuss targeted lipid goals according to established guideline recommendations; Describe pharmacological options for the management of dyslipidemia, including mechanisms of action, effects on lipid parameters, and adverse drug reactions; Recommend pharmacological and non-pharmacological treatment options for a given patient with diabetes and dyslipidemia; Describe the role of the pharmacist in managing dyslipidemia and successful examples of such interventions. Upon completion technicians will be able to: Define dyslipidemia; Identify risk factors for cardiovascular diseases; List targeted lipid goals according to established guideline recommendations; List medications used for the management of dyslipidemia. **UAN: 0165-0000-10-083-L01-P UAN: 0165-0000-10-083-L01-T**

8:30am-10:00am **Education: 1.5 hrs GCE/RC/TECH**
Adverse Drug Reactions Associated with Antiarrhythmic Drug Therapy
Luigi Cubeddu, MD, PhD, NOVA Southeastern University, Professor. Upon completion of this activity pharmacists will be able to: List the most commonly used anti-arrhythmic drugs; Recognize their clinical indications; List the major adverse drug reactions associated with anti-arrhythmic medications; Describe what a long-QT is and the clinical implications of the long QT syndrome; List the drugs that prolong the QT interval and their association with fatal arrhythmias; Identify the role of pharmacists in preventing drug-induced fatal arrhythmias (Torsades). Upon completion technicians will be able to: Define arrhythmia; List signs or symptoms associated with arrhythmias; List medications used to manage arrhythmias. **UAN: 0165-0000-10-084-L01-P UAN: 0165-0000-10-084-L01-T**

10:00am-10:15am **Break**

10:15am-11:45am **Education: 1.5 hrs GCE/RC/TECH**
Update on the Management of Angina and Post-MI Patients
Teresa Schweiger, PharmD, LECOM University, Pharmacy Professor. Upon completion of this activity pharmacists will be able to: Explain the pathophysiology of stable and unstable angina and acute myocardial infarction; Recognize and counsel patients as to the differences between stable and unstable angina; Describe therapies used to manage symptoms in patients with stable angina; Identify treatments that are important to decreasing morbidity and mortality in all post-myocardial infarction patients. Discuss commonly used antiplatelet agents prescribed after MI and coronary interventions; Counsel patients about therapeutic lifestyle changes that help prevent recurrent myocardial infarction and death; Recognize commonly used over-the-counter medications that patients take but that have no benefit in preventing recurrent MI and death. Upon completion technicians will be able to: Define angina and acute myocardial infarction; Identify signs and symptoms associated with angina and MI; List medications used to treat angina and MI. **UAN: 0165-0000-10-085-L01-P UAN: 0165-0000-10-085-L01-P-T**

11:45am-1:15pm **Education: 1.5 hrs GCE/RC/TECH**
"Today's VTE" A Focus on Outpatient Anticoagulant Therapy
Norm Tomaka, RPh, CPh, Health First, Outpatient Consultant Pharmacist. Upon completion of this activity pharmacists will be able to: Recognize the signs and symptoms associated with VTE and CVA; Discuss emerging laboratory tests/technology used to diagnose both VTE and CVA; Explain available medications used to help prevent VTEs and CVAs from occurring; Discuss the advantages and disadvantages of each available drug; Discuss anticoagulants that are in the pipeline to help prevent VTE and CVA. Upon completion technicians will be able to: List signs and symptoms associated with VTE and CVA; Identify medications used to prevent VTEs and CVAs; Recognize newer agents that will be used to prevent VTE and CVA. **UAN: 0165-0000-10-086-L01-P UAN: 0165-0000-10-086-L01--T**

1:30pm-3:30pm **Education: 2 hrs GCE/TECH**
Reducing Medication Errors presented by Michael Jackson, RPh, CPh
UAN: 0165-0000-10-025-L05-P UAN: 0165-0000-10-025-L05-T
(See page 2 for details)

6:30am **Registration Desk Open**

7:00am-8:30am **Education: 1.5 hrs GCE/RC/TECH**
Review of Hypertension Management (JNC 1-7)
Marvin Scott, PharmD, Florida A&M University, Pharmacy Professor. Upon completion of this activity pharmacists will be able to: Discuss the importance of JNC; Identify cardiovascular risk factors; Identify drugs and discuss mechanisms of action of drugs discussed; Discuss the role of drugs discussed in the treatment of hypertension; Identify specific parameters to be monitored (e.g. physical findings, laboratory values, etc) in order to prevent or detect potential drug interactions or adverse effects; Construct a specific pharmaceutical care plan for a given patient with a specific disease and list of drugs to ensure positive therapeutic outcome. Upon completion technicians will be able to: Define hypertension; Identify cardiovascular risk factors; List medications used for hypertension management; Recognize the importance of JNC. **UAN: 0165-0000-10-087-L01-P UAN: 0165-0000-10-087-L01-T**


8:30am-10:00am **Education: 1.5 hrs GCE/RC/TECH**
An Update on the Management of Congestive Heart Failure
Marvin Scott, PharmD, Florida A&M University, Pharmacy Professor. Upon completion of this activity pharmacists will be able to: Identify cardiovascular risk factors; Identify drugs and discuss mechanisms of action of drugs discussed; Discuss the role of drugs discussed in the treatment of heart failure; Identify specific parameters to be monitored (e.g. physical findings, laboratory values, etc) in order to prevent or detect potential drug interactions or adverse effects; Construct a specific pharmaceutical care plan for a given patient with a specific disease and list of drugs to ensure positive therapeutic outcome. Upon completion technicians will be able to: Define congestive heart failure; Identify risk factors for heart failure; List medications used for the management of congestive heart failure. **UAN: 0165-0000-10-088-L01-P UAN: 0165-0000-10-088-L01-T**

10:00am-10:15am **Break**

10:15am-11:45am **Education: 1.5 hrs GCE/RC/TECH**
The Keys to Cardiovascular Wellness: Mind, Body, and Soul
Tara Henry, PharmD, South Georgia North Florida VA Medical Center, Clinical Pharmacist. Upon completion of this activity pharmacists will be able to: Create dietary options to improve cardiovascular health and wellness; Identify educational options to improve cardiovascular wellness; Discuss lifestyle changes to improve cardiovascular wellness. Upon completion technicians will be able to: Identify lifestyle changes to improve cardiovascular wellness; Identify the importance of education; Recognize the importance of a healthy diet. **UAN: 0165-0000-10-089-L01-P UAN: 0165-0000-10-089-L01-T**

11:45am-1:15pm **Education: 1.5 hrs GCE/RC/TECH**
The Skinny of Childhood Obesity and the Cardiovascular Consequences
Carol Motycka, PharmD, University of Florida, Assistant Dean and Campus Director - Jacksonville . Upon completion of this activity pharmacists will be able to: Discuss possible risk factors contributing to overweight and obesity in children; Identify possible causes for weight gain and obesity in children; Recognize potential cardiovascular complications associated with obesity in children; Describe treatment options for overweight and obese children and the cardiovascular risks that may be associated with them. Upon completion technicians will be able to: Identify risk factors that contribute to weight gain in children; Recognize the cardiovascular complication associated with obese children; List treatment options for obese children with cardiovascular risks. **UAN: 0165-0000-10-090-L01-P UAN: 0165-0000-10-090-L01-T**

1:30pm-2:30pm **Education: 1hr GCE/TECH**
HIV/AIDS presented by Michael Thompson, PharmD, BCNSP
UAN: 0165-0000-10-012-L02-P UAN: 0165-0000-10-012-L02-T
(See page 2 for details)



The Florida Pharmacy Association is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. Up to 18 contact hours are available upon successful completion of the program through attendance and submission of completed attendance and evaluation forms. Statements of continuing pharmacy education will be mailed four to six weeks after the program. Consultant recertification approval number applied for and pending. Initial laboratory certification approval number is 20-260344. number is . **This is an ACPE knowledge based activity.**